Fernando-Cruz Foundation Symposium, Hospital Clinico San Carlos, Madrid 2015
|
|
- Hilary Conley
- 6 years ago
- Views:
Transcription
1 Fernando-Cruz Foundation Symposium, Hospital Clinico San Carlos, Madrid 2015 Management of Hypercholesterolemia beyond Statins : ODYSSEY and OSLER Trials M. John Chapman BSc (Hons), Ph.D., D.Sc., FESC Director Emeritus, INSERM, Research Professor, University of Pierre and Marie Curie Past-President, European Atherosclerosis Society Pitié-Salpetriere University Hospital, Paris, France
2 PCSK9 Inhibitors: From Target Discovery to Phase III to the Clinic PCSK9 (NARC-1) discovered PCSK9 GOF mutations associated with ADH* PCSK9 LOF Mutations found with 28% LDL-C and 88% CHD risk Humans null for PCSK9 have LDL-C ~15 mg/dl Plasma PCSK9 binds to LDL-R First Patients with FH / non-fh treated with PCSK9i mab 1 st FDA / EMEA PCSK9i filing Adenoviral expression in mice PCSK9 KO mouse LDL-C First subject treated with PCSK9 mab LDL-C in mice and non-human primates treated with anti-pcsk9 mab First publication POC in patients * ADH: Autosomal Dominant Hypercholesterolemia; Seidah NG. Proc Natl Acad Sci US 2003;100(3):928-33, Abifadel M. Nat Genet 2003;34(2):154-6, Maxwell KN. Proc Natl Acad Sci US 2004;101(18):7100-5, Rashid S. Proc Natl Acad Sci US 2005;102(15): , Lagace TA et al. JCI 2006;116: Cohen JC. N Engl J Med 2006;354(12): , Zhao Z. Am J Hum Genet 2006;79(3):514-23, Hooper AJ. Atherosderosis 2007;193(2):445-8, Chan JC. Proc Natl Acad Sci US 2009;106(24):9820-5: Stein et at N Engl J Med 2012;366: ; Stein modified from Swergold, Regeneron.
3 CHOLESTEROL Cell membrane component Steroid hormone precursor Vitamin D precursor Bile acid precursor LXR agonist (oxysterols)
4 CHOLESTEROL HOMEOSTASIS NY /020131YlsjoLS1 WHOLE BODY Peripheral Tissue Cholesterol Pool Dietary Cholesterol NPC1L1 Biliary Cholesterol Intestine NPC1L1 Cholesterol Pool Synthesis CM Liver Cholesterol Pool Synthesis VLDL nascent HDL LDL HDL Synthesis Skin Cholesterol Pool Synthesis Endocrine Glands Cholesterol Pool Excretion Skin Sterols 85 mg/j Steroïd Hormones 50 mg/j Synthesis Biliary Cholesterol 600 mg/j Bile Acids 400 mg/j
5 Thin cap, rupture-prone atherosclerotic plaque Thin cap Inflammation - macrophages - T lymphocytes - mast cells Cholesterol crystals Lipid-rich core Courtesy: Erling Falk
6 LDL is causal in the pathophysiology of atherosclerotic vascular disease INTERHEART Familial hypercholesterolemia RCTs with statins and cholesterol absorption inhibition Mendelian randomisation studies PCSK9 genetics Origin of Plaque components Modulation of Plaque composition and size by Statins
7 Control of plasma LDL- cholesterol levels: Key role of the cellular LDL receptor [Accessed 6 August 2015] DOMAINS Ligand binding (292 (292 aa) aa) NH I II III IV V VI VII EXONS A B Epidermal growth factor precursor homology (400 aa) C O-linked sugars (58 aa) Membranespanning (22 aa) Cytoplasmic (50 aa) COOH
8 Plasma LDL degradation by the LDL Receptor pathway ER Golgi LDL LDLR Endosome (H + ) Coated vesicle Coated pit Lysosome (H + ) Recycling vesicle
9 Which factors principally control levels of LDL receptor activity in the liver?
10 Control of hepatic LDL-Receptor activity - Intracellular levels of cholesterol (reflecting uptake of cholesterol contained in LDL, VLDL and chylomicron remnants, and HDL), endogenous cholesterol synthesis, cholesterol conversion to bile acids, and excretion of bile acids and biliary cholesterol) via the SREBP pathway - PCSK9 - the IDOL pathway
11 Control of hepatic LDL-Receptor activity - Intracellular levels of cholesterol (reflecting uptake of cholesterol contained in LDL, VLDL and chylomicron remnants, and HDL), endogenous cholesterol synthesis, cholesterol conversion to bile acids, and excretion of bile acids and biliary cholesterol) via the SREBP pathway - PCSK9 - the IDOL pathway
12 What is PCSK9? How was PCSK9 identified as a key gene in cholesterol homeostasis?
13 What is PCSK9? Chromosome: 1p32.3 Gene: 12 exons cdna 3617 bp Protein: 692 amino acids Expressed in liver, kidney, intestine Undergoes autocatalytic cleavage in the ER to active conformation Appears to play the role of an intracellular protein chaperone [Accessed 19 July 2011] Abifadel M, et al. Nature Genet 2003;34: Horton JD, et al. Trends Biochem Sci 2007;32:71 7. Abifadel M, et al. Hum Mutat 2009;30: Chen SN, et al JACC 2005;45:
14 A PCSK9 GAIN-of-Function mutation causes Autosomal Dominant Hypercholesterolaemia Affected family members with: Total cholesterol in 90 th percentile Tendon xanthomas CHD Early MI Stroke Abifadel M, et al. Nat Genet 2003;34:154 6.
15 Absence of PCSK9 Leads to Marked Increase in LDL-R PCSK9 knockout mice : hepatic LDL-R levels Immunoblot Immunofluorescence against LDL-R PCSK9 decreases number of LDL-R : LDL-C Rashid S et al. PNAS 2005;102:
16 Role of PCSK9 in regulation of the surface expression of LDL receptors LDL particles LDL-R PCSK9 routes LDL-R for lysosomal degradation LDL-R recycling blocked PCSK9 secretion Chan JC, et al. Proc Natl Acad Sci USA 2009;106:
17 Regulation of PCSK9 is dynamic Upregulates PCSK9 Cholesterol depletion 2,3 SREBP2 1,3,4 Statins 3,4 Plasma PCSK9 level Downregulates PCSK9 Dietary and cellular cholesterol 4 Bile acids 3,4 1. Horton JD, et al. J Lipid Res. 2009;50:S Lopez D. Biochem Biophys Acta 2008;1781: Abifadel M, et al. Hum Mutat. 2009;30: supplementary information. 4. Abifadel M, et al. In: Toth PP. The Year in Lipid Disorders. Vol. 2. Oxford, UK: Atlas Medical Publishing Ltd. 2010: Miao et al, ATVB. 2015;35:
18 Is there a major flaw In the MOA of statins?
19 Mechanism of statin-mediated upregulation of the LDLR gene via SREBP2 LDL-C Statin Lysosomal degradation LDLR SREBP2 Hepatocyte
20 Mechanism of statin-mediated upregulation of the LDLR and PCSK9 genes via SREBP2 LDL-C Statin Lysosomal degradation LDLR SREBP2 PCSK9 Hepatocyte Adapted from Konrad RJ et al. Lipids Health Dis 2011;10:38.
21 PCSK9 How do genetic mutations/variants in PCSK9 relate to LDL-C levels and CV risk? Can PCSK9 be targeted to reduce LDL-C and CVD?
22 Genetic variants of PCSK9 exert distinct roles in regulating LDL-C levels Lysosomal degradation of LDLR Plasma Recycling of LDLR Nucleus Already in JC presentation but I will get better picture quality for both Gain-of-function mutation Loss-of-function mutation Golgi apparatus Gain-of-function PCSK9 PCSK9 secretion Loss-of-function PCSK9 Plasma PCSK9 Gain of Function = Less LDLRs PCSK9 Loss of Function = More LDLRs
23 Elevated LDL-C levels in patients with GAIN-of-Function PCSK9 mutations Control 105 D35Y L108R RARE S127R 287 F216L R218S D374Y 350 Poirier S, Mayer G. Drug Des Devel Ther 2013;7:
24 Low LDL-C levels in patients with LOSS-of-Function PCSK9 mutations Control 105 R46L 86 R97 G106R FREQUENT Y142X 53 C679X 68 Poirier S, Mayer G. Drug Des Devel Ther 2013;7:
25 Frequency (%) Loss-of-Function PCSK9 mutations are associated with low LDL-C and low prevalence of CHD events Coronary Heart Disease (%) No nonsense mutation (n = 3278) 50 th Percentile Mean 138 mg/dl 88% reduction in risk of CHD events during 15-year follow-up % PCSK9 142x or PCSK9 679X (n=85) Mean 100 mg/dl (-28%) % Plasma LDL-C in black subjects (mg/dl) No Yes PCSK9 142x or PCSK9 679X Adapted from Cohen JC et al. N Engl J Med 2006;354:
26 Individuals who completely lack PCSK9 and have very low LDL-C levels are healthy Therefore, inhibition of PCSK9 may be a safe pharmacologic approach to dyslipidaemia management
27 Approaches to reducing PCSK9 interaction with the LDLR Bind plasma PCSK9 Monoclonal antibodies Evolocumab, now EMEA approved (Amgen) Alirocumab, now FDA approved (Regeneron/Sanofi) Bococizumab (Pfizer) Adnectins (Adnexis/BMS) Reduce PCSK9 synthesis sirna (Alnylam) Lambert G, et al. J Lipid Res : [Accessed 6 August 2015]
28 Impact of an anti-pcsk9 monoclonal antibody on LDL-R expression Anti-PCSK9 mab PCSK9 Increased LDLR surface concentration LDLR LDLR recycling Chan JC, et al. Proc Natl Acad Sci USA 2009;106:
29 Free/total PCSK9 Conc. (ng/ml) Total alirocumab (ng/ml) X 0.01 LDL-C mean % change Alirocumab: Dynamic Relationship Between mab Levels, PCSK9 and LDL-C Total alirocumab Free PCSK9 LDL-C W Time (hours) -70 Stein EA et al. New Engl J Med 2012;366:
30 The CV Risk Pyramid : Greatest clinical needs Familial Hypercholesterolemia (HeFH and HoFH) LDL-C levels often far from goal, even with potent statins and combination therapies Life-long exposure to high LDL-C; considered high risk even w/o additional risk factors High CV Risk Patients Patients not at LDL-C goal with currently available LLT (even high doses of potent statins) and persistent high risk Statin Intolerant Patients LDL-C levels often far from goal, due to intolerance Patients unable to tolerate at least 2 statins, including one at the lowest dose
31 Auto-immune disorders Chronic kidney disease (SHARP) Acute Coronary Syndromes Very high and high risk Dyslipidaemic patient populations Stable; Unstable CAD Ischaemic Stroke Metabolic syndrome Type 2 diabetes FH Non-FH hyperchol Chapman, MJ. Unpublished.
32 Overview of ODYSSEY Clinical Trial Program 14 global phase 3 trials including >23,500 patients across >2,000 study centers HeFH population HC in high CV risk population Additional populations Add-on to max-tolerated statin (± other LMT) ODYSSEY FH I (NCT ; EFC12492) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=471; 18 months ODYSSEY FH II (NCT ; CL1112) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=250; 18 months Add-on to max-tolerated statin (± other LMT) ODYSSEY COMBO I (NCT ; EFC11568) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=306; 12 months *ODYSSEY COMBO II (NCT ; EFC11569) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=660; 24 months ODYSSEY MONO (NCT ; EFC11716) Patients on no background LMTs LDL-C 100 mg/dl N=100; 6 months ODYSSEY ALTERNATIVE (NCT ; CL1119) Patients with defined statin intolerance LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=250; 6 months ODYSSEY HIGH FH (NCT ; EFC12732) LDL-C 160 mg/dl N=105; 18 months ODYSSEY OLE (NCT ; LTS 13463) Open-label study for FH from EFC 12492, CL 1112, EFC or LTS N 1000; 30 months ODYSSEY LONG TERM (NCT ; LTS11717) LDL-C 70 mg/dl N=2,100; 18 months ODYSSEY CHOICE I (NCT ; CL1308) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=700; 12 months ODYSSEY OUTCOMES (NCT ; EFC11570) LDL-C 70 mg/dl N=18,000; 64 months ODYSSEY CHOICE II (NCT ; EFC13786) Patients not treated with a statin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=200; 6 months ODYSSEY OPTIONS I (NCT ; CL1110) Patients not at goal on moderate dose atorvastatin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=350; 6 months ODYSSEY OPTIONS II (NCT ; CL1118) Patients not at goal on moderate dose rosuvastatin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=300; 6 months FH=familial hypercholesterolemia; HC=hypercholesterolemia; LMT=lipid-modifying therapy; OLE=open-label extension. *For the ODYSSEY COMBO II other LMT not allowed at entry. ClinicalTrials.gov. ODYSSEY Trials. Accessed February 12, 2014.
33 Evolocumab Clinical Trial Program Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations (Latin): To advance To make progress 33
34 Evolocumab s PROFICIO clinical trial program addresses key areas of unmet need in the management of dyslipidaemia Combination therapy Monotherapy Phase 2 (n=631) Phase 2 (n=411) >35,000 patients (n=2067) (n=615) Statin intolerant Phase 2 (n=160) (n=307) (n=511)* HeFH HoFH/ Severe FH Phase 2 (n=168) Phase 2/3 (n=58) (n=331) Phase 2/3 (n=300) Completed trials Long-term safety and efficacy Open-label extension Atherosclerosis Secondary Prevention Neurocognition Phase 2 (n=1104) (n=905) (n=3671)* (n=970) (n=27,564) (n=1971)* HeFH, heterozygous hypercholesterolaemia; HoFH, homozygous hypercholesterolaemia. Clintrials.gov. * Amgen data on file.
35 SPIRE Bococizumab Clinical Development Programme Unmet Needs in the Management of CVD in High Risk Patients SPIRE (Studies of PCSK9 Inhibition and the Reduction of Vascular Events) N=~30,000 SPIRE Lipid Lowering Studies SPIRE CV Outcome Studies SPIRE HR (n=300) On statin High risk of CV event LDL-C 70 or 100 mg/dl SPIRE LDL (n=1,932) On statin High risk of CV event LDL-C 70 mg/dl SPIRE-1 (n=17,000) High Risk Primary and Secondary Prevention LDL-C 70 to <100 mg/dl on statins (or statin intolerant) SPIRE-2 (n=9,000) High Risk Primary and Secondary Prevention LDL-C 100 mg/dl on statins (or statin intolerant) SPIRE FH (n=300) HeFH (genetic diagnosis or Simon Broome Criteria), LDL >70 mg/dl SPIRE LL (n=690) On statin High / very high risk of CV event LDL-C 100 mg/dl NCT#: SPIRE HR: NCT SPIRE LDL: NCT SPIRE HF: NCT SPIRE SI (n=150) Statin intolerant LDL-C 70 mg/dl Studies on PCSK9 Inhibition and the Reduction of Vascular Events SPIRE-LL: NCT SPIRE-SI: NCT SPIRE-1: NCT SPIRE-2: NCT
36 Overview of ODYSSEY Clinical Trial Program 14 global phase 3 trials including >23,500 patients across >2,000 study centers HeFH population HC in high CV risk population Additional populations Add-on to max-tolerated statin (± other LMT) ODYSSEY FH I (NCT ; EFC12492) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=471; 18 months ODYSSEY FH II (NCT ; CL1112) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=250; 18 months Add-on to max-tolerated statin (± other LMT) ODYSSEY COMBO I (NCT ; EFC11568) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=306; 12 months *ODYSSEY COMBO II (NCT ; EFC11569) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=660; 24 months ODYSSEY MONO (NCT ; EFC11716) Patients on no background LMTs LDL-C 100 mg/dl N=100; 6 months ODYSSEY ALTERNATIVE (NCT ; CL1119) Patients with defined statin intolerance LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=250; 6 months ODYSSEY HIGH FH (NCT ; EFC12732) LDL-C 160 mg/dl N=105; 18 months ODYSSEY OLE (NCT ; LTS 13463) Open-label study for FH from EFC 12492, CL 1112, EFC or LTS N 1000; 30 months ODYSSEY LONG TERM (NCT ; LTS11717) LDL-C 70 mg/dl N=2,100; 18 months ODYSSEY CHOICE I (NCT ; CL1308) LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=700; 12 months ODYSSEY OUTCOMES (NCT ; EFC11570) LDL-C 70 mg/dl N=18,000; 64 months ODYSSEY CHOICE II (NCT ; EFC13786) Patients not treated with a statin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=200; 6 months ODYSSEY OPTIONS I (NCT ; CL1110) Patients not at goal on moderate dose atorvastatin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=350; 6 months ODYSSEY OPTIONS II (NCT ; CL1118) Patients not at goal on moderate dose rosuvastatin LDL-C 70 mg/dl OR LDL-C 100 mg/dl N=300; 6 months FH=familial hypercholesterolemia; HC=hypercholesterolemia; LMT=lipid-modifying therapy; OLE=open-label extension. *For the ODYSSEY COMBO II other LMT not allowed at entry. ClinicalTrials.gov. ODYSSEY Trials. Accessed February 12, 2014.
37 OLE/8 week FU ODYSSEY FH I and FH II Study Design Double-Blind Treatment Period (78 Weeks) HeFH patients on max tolerated statin ± other lipidlowering therapy LDL-C 1.81 mmol/l [70 mg/dl] (history of CVD) or 2.59 mmol/l [100 mg/dl] (no history of CVD) R Alirocumab 75 mg Q2W SC with potential to 150 mg Q2W SC (single 1-mL injection using prefilled pen for self-administration) n=323 (FH I); n=167 (FH II) n=163 (FH I); n=82 (FH II) Placebo Q2W SC Per-protocol dose possible based on pre-specified LDL-C level Assessments W0 W8 W16 W36 W64 W4 W12 W24 W52 W78 Dose if LDL-C >70 mg/dl at W8 Primary efficacy endpoint Pre-specified analysis Efficacy: All Patients To W52 Safety: Baseline-W78 (all patients at least W52) Clinicaltrials.gov identifiers: ODYSSEY FH I: NCT ; ODYSSEY FH II: NCT Kastelein, ESC 2014
38 Lipid Medication and LDL-C at Baseline All patients on background of max-tolerated statin ± other lipid-lowering therapy Alirocumab (N=323) FH I Placebo (N=163) Alirocumab (N=167) FH II Placebo (N=82) Any statin, % (n) 100% 100% 100% 100% High-intensity statin, % (n) 80.8% (261) 82.8% (135) 86.2% (144) 87.8% (72) Ezetimibe, % (n) 55.7% (180) 59.5% (97) 67.1% (112) 64.6% (53) LDL-C, mean (SD), mmol/l [mg/dl] 3.7 (1.3) [144.7 (51.2)] 3.7 (1.2) [144.4 (46.8)] 3.5 (1.1) [134.6 (41.3)] 3.5 (1.1) [134.0 (41.6)] Patients should receive either rosuvastatin mg, atorvastatin mg daily, or simvastatin 80 mg daily unless not tolerated and/or appropriate other dose given according to the judgement of the investigator. High-intensity statin: atorvastatin mg or rosuvastatin mg daily. Kastelein, ESC 2014
39 LS mean (SE) % change from baseline to Week 24 Alirocumab Significantly Reduced LDL-C from Baseline to Week 24 versus Placebo Primary Endpoint: % Change from Baseline to Week 24 in LDL-C FH I FH II Alirocumab Placebo N=322 N=163 N=166 N= % had dose increase at W % had dose increase at W12 LS mean difference (SE) vs. placebo: 57.9% (2.7) P< % (3.4) P< Intent-to-treat (ITT) Analysis Kastelein, ESC 2014
40 Evolocumab s PROFICIO clinical trial program addresses key areas of unmet need in the management of dyslipidaemia Combination therapy Monotherapy Phase 2 (n=631) Phase 2 (n=411) >35,000 patients (n=2067) (n=615) Statin intolerant Phase 2 (n=160) (n=307) (n=511)* HeFH HoFH/ Severe FH Phase 2 (n=168) Phase 2/3 (n=58) (n=331) Phase 2/3 (n=300) Completed trials Long-term safety and efficacy Open-label extension Atherosclerosis Secondary Prevention Neurocognition Phase 2 (n=1104) (n=905) (n=3671)* (n=970) (n=27,564) (n=1971)* HeFH, heterozygous hypercholesterolaemia; HoFH, homozygous hypercholesterolaemia. Clintrials.gov. * Amgen data on file.
41 Evolocumab Q2W or QM: consistent LDL-C reductions across different studies Evolocumab vs placebo: consistent reduction in LDL-C, Q2W and QM Evolocumab vs ezetimibe: consistent reduction in LDL-C, Q2W and QM Treatment difference for % change from baseline in LDL-C Monotx MENDEL-2 N=614 Combotx LAPLACE-2 N=1896 HeFH RUTHERFORD-2 N=329 Long Term DESCARTES N=901 Monotx MENDEL-2 N=614 Combotx LAPLACE-2 N=1896 SI GAUSS-2 N=307 Evolocumab 140 mg Q2W Evolocumab 420 mg QM Results are for the mean of weeks 10 and 12 except for DESCARTES, which are for week 52. MENDEL-2: Koren MJ, et al. J Am Coll Cardiol 2014;63: ; LAPLACE-2: Robinson JG, et al. JAMA 2014;311: ; RUTHERFORD-2: Raal FJ, et al. Lancet 2015;385:331 40; DESCARTES: Blom DJ, et al. N Engl J Med 2014;370: ; GAUSS-2: Stroes E, et al. J Am Coll Cardiol 2014;63:
42 Evolocumab s PROFICIO clinical trial program addresses key areas of unmet need in the management of dyslipidaemia Combination therapy Monotherapy Phase 2 (n=631) Phase 2 (n=411) >35,000 patients (n=2067) (n=615) Statin intolerant Phase 2 (n=160) (n=307) (n=511)* HeFH HoFH/ Severe FH Phase 2 (n=168) Phase 2/3 (n=58) (n=331) Phase 2/3 (n=300) Completed trials Long-term safety and efficacy Open-label extension Atherosclerosis Secondary Prevention Neurocognition Phase 2 (n=1104) (n=905) (n=3671)* (n=970) (n=27,564) (n=1971)* HeFH, heterozygous hypercholesterolaemia; HoFH, homozygous hypercholesterolaemia. Clintrials.gov. * Amgen data on file.
43 Raal FJ et al. Lancet 2015; 385: Figure 2
44 Efficacy of LDL-C lowering by Evolocumab in heterozygous FH patients : RUTHERFORD-2 Evolocumab 140 mg Q2W Evolocumab 420 mg QM Raal FJ, et al. Lancet 2014; doi.org/ /s (14) and supplementary material.
45 45 On treament residual LDL= 280 mg/dl
46 TAUSSIG Raal 46et al ISA 2015
47 Cuchel et al, EHJ 2014
48 Evolocumab s PROFICIO clinical trial program addresses key areas of unmet need in the management of dyslipidaemia Combination therapy Monotherapy Phase 2 (n=631) Phase 2 (n=411) >35,000 patients (n=2067) (n=615) Statin intolerant Phase 2 (n=160) (n=307) (n=511)* HeFH HoFH/ Severe FH Phase 2 (n=168) Phase 2/3 (n=58) (n=331) Phase 2/3 (n=300) Completed trials Long-term safety and efficacy Open-label extension Atherosclerosis Secondary Prevention Neurocognition Phase 2 (n=1104) (n=905) (n=3671)* (n=970) (n=27,564) (n=1971)* HeFH, heterozygous hypercholesterolaemia; HoFH, homozygous hypercholesterolaemia. Clintrials.gov. * Amgen data on file.
49 OSLER Program Phase 2 trials MONO- THERAPY MENDEL-1 (n=406) HYPERCHOL ON A STATIN LAPLACE-TIMI 57 (n=629) STATIN- INTOL GAUSS-1 (n=157) HETEROZYG FAM HYPERCHOL RUTHERFORD-1 (n=167) OTHER YUKAWA-1 (n=307) trials MENDEL-2 (n=614) LAPLACE-2 (n=1896) GAUSS-2 (n=307) RUTHERFORD-2 (n=329) DESCARTES (n=901) THOMAS-1 (n=149) THOMAS-2 (n=164) 4465 patients (74%) elected to enroll into OSLER extension study program 1324 from Ph2 trials into OSLER from Ph3 trials into OSLER-2 Eligible if medically stable and on study drug Randomized 2:1 Irrespective of treatment assignment in parent study Evolocumab plus standard of care (n=2976) Standard of care alone (n=1489) Trial Sponsor: Amgen Median follow-up of 11.1 months (IQR ) 7% discontinued evolocumab early 96% completed follow-up Sabatine et al. N Engl J Med 2015; March 15: online
50 LDL Cholesterol Standard of care alone 61% reduction (95%CI 59-63%), P< Absolute reduction: 73 mg/dl (95%CI 71-76%) Evolocumab plus standard of care (Parent study) (OSLER) N=4465 N=1258 N=4259 N=4204 N=1243 N=3727 Sabatine et al. N Engl J Med 2015; March 15: online
51 Change from Baseline (%) Change from Baseline (%) Change from Baseline (%) Change from Baseline (%) Change from Baseline (%) Change from Baseline (%) Other Lipid Parameters 52% in Non-HDL-C 47% in ApoB 26% in Lp(a) P< P< P< % in Triglycerides 7% in HDL-C 4% in ApoA P< P< P< Week 12 data; values are means except for TG and Lp(a) which are medians Standard of care alone Evolocumab plus standard of care Sabatine et al. N Engl J Med 2015; March 15: online
52 Mean % Change from Baseline Evolocumab 140 mg Q2W or 420 mg Q4W: Effect of Baseline TG on TG response N TG <150 mg/dl TG mg/dl TG >250 mg/dl Mean TG 99.2 mg/dl Mean TG mg/dl Mean TG mg/dl With permission from Dr E. Stein
53 Cumulative Incidence (%) Sabatine et al. N Engl J Med 2015; March 15: online Cardiovascular Outcomes 3 Composite Endpoint: Death, MI, UA hosp, coronary revasc, stroke, TIA, or CHF hosp 2 1 HR % CI P=0.003 Standard of care alone (N=1489) 2.18% 0.95% 0 Evolocumab plus standard of care (N=2976) Days since Randomization
54 Estimated probability of event Robinson et al. N Enl J Med 2015; March 15: online Post-hoc Adjudicated Cardiovascular TEAEs (Same as primary endpoint of ongoing ODYSSEY OUTCOMES trial ) Kaplan-Meier Estimates for Time to First Adjudicated Major CV Event Safety Analysis (at least 52 weeks for all patients continuing treatment, including 607 patients who completed W78 visit) 0.10 Placebo + max-tolerated statin ± other LLT Alirocumab + max-tolerated statin ± other LLT Cox model analysis: HR=0.46 (95% CI: 0.26 to 0.82) Nominal p-value = <0.01 Mean treatment duration: 65 weeks No. at Risk Placebo Alirocumab Weeks Primary endpoint for the ODYSSEY OUTCOMES trial: CHD death, Non-fatal MI, Fatal and non-fatal ischemic stroke, Unstable angina requiring hospitalisation. LLT, lipid-lowering therapy
55 Coronary disease & death before age 20 Untreated coronary disease before age 55/60 Cumulative LDL-C (mmol) HOZ Untreated Treat at 10yrs Non FH Treat at 18yrs Homozygous FH Heterozygous FH yrs Start low dose statin Threshold for CHD Start high dose statin 35yrs Without FH Age in years Years Age 48yrs 53yrs 55yr Female sex Smoking Hypertension Diabetes Triglycerides HDL-C Lipoprotein(a) Nordestgaard et al, EHJ 2013; EAS Consensus Panel
56 Sabatine et al. N Engl J Med 2015; March 15: online Safety Adverse events (%) Evolocumab + stnd of care (N=2976) Standard of care alone (N=1489) Any Serious Leading to discontinuation of evolocumab 2.4 n/a Injection-site reactions 4.3 n/a Muscle-related Neurocognitive Laboratory results (%) ALT or AST >3 ULN Creatine kinase >5 ULN
57 Sabatine et al. N Engl J Med 2015; March 15: online Adverse Events by Achieved LDL-C Adverse Events (%) Evolocumab subjects stratified by minimum achieved LDL-C <25 mg/dl (n=773) 25 to <40 mg/dl (n=759) <40 mg/dl (n=1532) 40 mg/dl (n=1426) All EvoMab (n=2976) Stnd of Care Alone (n=1489) Any Serious Muscle-related Neurocognitive Lab results (%) ALT/AST >3 ULN CK >5 ULN
58 Trials: Alirocumab, Evolocumab, Bococizumab Patient Pop n Evolocumab (PROFICIO program) Alirocumab (ODYSSEY program) Bococizumab (SPIRE program) Trial N Dur n (m) Predicted Pt Exposure (Y) Min B/L LDL-C (mg/dl) Trial N Dur n (m) Predicted Pt Exposure (Y) Min B/L LDL- C (mg/dl) Trial N Dur n (m) Predicted Pt Exposure (Y) Min B/L LDL- C (mg/dl) HeFH RUTHERFORD FH I FH II FH >70 HAUSER (paeds) HIGH FH TESLA HoFH TAUSSIG (OL) COMBO I HR >70 Combo Therapy LAPLACE COMBO II OPTIONS I LDL >70 OPTIONS II Monotherapy MENDEL MONO AI Statin Intolerance GAUSS None GAUSS None ALTERNATIVE SI Long term DESCARTES LONG-TERM OSLER-2 (OL) None OLE (OL) None LL Atheroma GLAGOV Totals Patients Predicted Pt Yrs ~ 9943 Patients 5465 Predicted Pt Yrs ~ 7302 Patients 3972 Predicted Pt Yrs ~ 2421 CVD Outcomes FOURIER 27,564 Event driven NA 70 OUTCOMES 18,000 Event driven NA 70 SPIRE-1 17,000 SPIRE-2 9,000 Event driven Event driven NA 70 & <100 NA 100 Neurocognitive events EBBINGHAUS 1971 in FOURIER End of FOURIER N/A 70 For Predicted Pt Exposure, where randomization is unknown, assumed 2:1 in favour of active comparator; Assumed 1:1:1 randomization; Patients from 4 studies: FH1, FH2, High FH and Long-term. EUHQ-NP References to support data: see slide notes No head-to-head studies available. No direct study comparison intended. This overview is intended to be used for scientific illustrative purposes only.
59 PCSK9 mab Outcomes Trials Study FOURIER ODYSSEY OUTCOMES SPIRE-1 SPIRE-2 Who? Patients aged with history of clinically evident CVD at high risk for recurrent event Patients aged 40 hospitalized for ACS recently (<52 weeks) Background lipid lowering treatment and at high risk of a CV event N 27,500 18,000 17, Primary endpt Time to CV death, MI, hospitalization for UA, stroke, or coronary revasc, whichever occurs first Time to CHD death, any nonfatal MI, fatal and non-fatal ischemic stroke, hospitalization for UA Confirmed major cardiovascular event [CV death, non- fatal MI, non-fatal stroke, and hospitalization for UA needing urgent revascularization] LDL-C 70 mg/dl (or non- HDL-C 100 mg/dl) 70 mg/dl 70 and <100 mg/dl (or non- HDL-C 100 mg/dl and <130 mg/dl) 100 mg/dl (or non HDL C 130 mg/dl) 59
60 PCSK9 Education and Research Forum is the major, globally-recognized academic resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Register at
61 1 OSLER-1: Phase 2 programme Open-label Study of Long-term Evaluation Against LDL-C Patients with hyperlipidaemia and mixed dyslipidaemia Completed a qualifying evolocumab Phase 2 parent study Eligible if medically stable and on study drug Age 18 to 75 years n=1104 R A N D O M I Z E D 2:1, irrespective of treatment assignment in parent study Evolocumab 420 mg QM + standard of care (n=736) Standard of care alone (n=368) Koren et al. Circulation 2014;129: At Week 52, patients in the evolocumab + SOC group achieved an LDL-C reduction of 52% (SE, 1%)
62 1 OSLER subpopulations: patients with T2DM, IFG or MetS Disease categorization (parent-study baseline): T2DM (n=72): By patient history IFG (n=95): No T2DM, but presence of FPG 110 mg/dl and < 126 mg/dl MetS (n=291): No T2DM, and presence of 3 IDF criteria Presented by Henry RR, et al. American Association of Clinical Endocrinologists, Las Vegas, NV. May 2014.
63 1 OSLER: Conclusions In patients with T2DM, IFG or MetS: Evolocumab (420 mg monthly) treatment reduced LDL-C by up to 52% (P < 0.001) at week 52 Reductions were comparable to those observed in patients without these three conditions Evolocumab dosed monthly demonstrated encouraging safety and tolerability at 1 year of treatment Presented by Henry RR, et al. American Association of Clinical Endocrinologists, Las Vegas, NV. May 2014.
64 Median FPG (mg/dl) Median HbA1c (%) 1 Time course of plasma levels of FPG and HbA1C Patients with T2DM Patients with IFG Patients with MetS Patients without MetS, IFG or T2DM Presented by Henry RR, et al. American Association of Clinical Endocrinologists, Las Vegas, NV. May 2014.
65 PCSK9 inhibition : The Future 1) Cardiovascular outcomes in Phase III trials 2) Impact on atherosclerotic vascular disease (AVD) 3) Impact of TGRL, remnant and Lp(a) lowering, and possibly HDL raising, on progression of AVD and CV events 3) Long term, real life, safety data from post-marketing surveillance 4) Evaluation of efficacy in other patient populations at high risk
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationPCSK9 Inhibitors: A View of Clinical Studies
PCSK9 Inhibitors: A View of Clinical Studies Slide deck kindly donated for website use by Professor Raul D. Santos Lipid Clinic InCor-HCFMUSP Sao Paulo, Brazil PCSK9 Inhibitors : A View of Clinical Studies
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationPCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?
PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis
More informationInhibition de PCSK9 : Mecanisme et Impacts sur la Plaque d Atherome
JPS, AE2BM 216 : Museum National d Histoire Naturelle, Paris Is there a clinical need Inhibition de PCSK9 : Mecanisme et Impacts sur la Plaque d Atherome for additional lowering agents? M. John Chapman
More informationPCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationBeyond HDL: new therapeutic targets
Rome Cardiology Forum 2014 An ESC Update Programme in Cardiology Rome, 29-31 2014 Beyond HDL: new therapeutic targets Marcello Arca, MD Dipartimento di Medicina Interna e Specialità Mediche UOS Centro
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationManagement of Dyslipidaemias: PCSK9 Inhibition. Alberico L. Catapano Professor President EAS University of Milano Italy
Management of Dyslipidaemias: PCSK9 Inhibition Alberico L. Catapano Professor President EAS University of Milano Italy Conflict of interest Grants, consulting fees and/or honoraria and delivering lectures
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationEfficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies
Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Michael J. Koren, 1 Evan A. Stein, 2 Eli M. Roth, 3 James M. McKenney, 4 Dan Gipe,
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationInvestigator Meeting. Monday, September 12, 2016
Investigator Meeting Monday, September 12, 2016 Principal Investigators Milan Gupta, MD, FRCPC, FACC Associate Clinical Professor of Medicine, McMaster University Brampton, ON Steering Committee David
More informationProblem patients in primary care Patient 4: Peripheral artery disease
Problem patients in primary care Patient 4: Peripheral artery disease Dr Terry McCormack Hambleton Richmond Whitby Clinical Commissioning Group Research Lead 01/05/2014 Delivering clinical research to
More informationHypercholesterolaemia is there a place for PCSK9-inhibitor therapy?
Hypercholesterolaemia is there a place for PCSK9-inhibitor therapy? Derick Raal FCP(SA), FRCP, FRCPC, Cert Endo, MMED, PHD Head, Division of Endocrinology & Metabolism Director, Carbohydrate and Lipid
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationAntisense and Antibodies as Game changers in refractory dyslipidemia. Erik Stroes AMC
Antisense and Antibodies as Game changers in refractory dyslipidemia Erik Stroes AMC Asymptomatic phase Plaque rupture There is a significant residual CVD risk at least partially modifiable Postponement
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationW J C. World Journal of Cardiology. PCSK9 inhibitors: A new era of lipid lowering therapy. Abstract REVIEW
W J C World Journal of Cardiology Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.4330/wjc.v9.i2.76 World J Cardiol 2017 February 26; 9(2): 76-91 ISSN 1949-8462 (online) REVIEW PCSK9 inhibitors:
More informationCost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.
Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationGuidelines on Lowering LDL-C Levels
Scientific Insights Into LDL-C, PCSK9, and CV Risks High circulating LDL-C levels are associated with increased risk for ASCVD 1,2 Statin drugs interfere with cholesterol production, lowering serum LDL-C
More informationFrom Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert
Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationEvolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia
Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Evolocumab (Repatha,
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationAlirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia
Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Alirocumab (Praluent,
More informationSystematic review of published Phase 3 data on anti-pcsk9 monoclonal antibodies in patients with hypercholesterolaemia
British Journal of Clinical Pharmacology SYSTEMATIC REVIEW Br J Clin Pharmacol (2016) 82 1412 1443 1412 Systematic review of published Phase 3 data on anti-pcsk9 monoclonal antibodies in patients with
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationPCSK9 inhibition in familial hypercholesterolemia: A revolution in treatment
PCSK9 inhibition in familial hypercholesterolemia: A revolution in treatment Frederick Raal FCP(SA), FRCP, FCRPC, Cert Endo, MMED, PHD Head, Division of Endocrinology & Metabolism Director, Carbohydrate
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationChallenges in lipid management
Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationObjectives. Hypercholesterolemia and Coronary Heart Disease. LDL Cholesterol. Hypercholesterolemia Is a Global Public Health Epidemic
12:3 1:45 pm Dyslipidemia in Primary Care: New Guideline Recommendations and Treatment Options SPEAKERS Carl E. Orringer, MD, FACC, FNLA James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA Presenter Disclosure
More informationLong-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM
Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Efficacy by subgroup, and safety when LDL-C
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationResults of ODYSSEY OUTCOMES Trial
Results of ODYSSEY OUTCOMES Trial Evaluation of long-term cardiovascular outcomes after Acute Coronary Syndrome (ACS) during treatment with Praluent (alirocumab) Investor call at ACC, Orlando, March 10,
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationWhats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?
Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationPCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION PCSK9 Inhibitors Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationParadim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie
Paradim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie Prof. G.Kees Hovingh, MD PhD MBA Dept. Vascular Medicine Academic Medical Center Amsterdam, the Netherlands Risk and profit
More informationDrug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors Final Original Report July 2015 The purpose of reports is to make available information regarding the comparative clinical
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationPCSK9 inhibition in homozygous familial hypercholesterolaemia
PCSK9 inhibition in homozygous familial hypercholesterolaemia Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis Research Center
More informationInclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia
ORION-1 Trial Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHA St Michael s Hospital, Toronto 1 Presented on behalf
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationMarch 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC
A Phase 3 Double-blind, Randomized Study to Assess Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin Erik Stroes 1, David Colquhoun
More information2017 Update in Internal Medicine: Clinical Dyslipidemia Update
2017 Update in Internal Medicine: Clinical Dyslipidemia Update Erin E. Kershaw, M.D. Chief, Division of Endocrinology Associate Professor of Medicine Certified in Endocrinology, Diabetes, and Metabolism
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationDrug Class Prior Authorization Criteria PCSK9 Inhibitors
Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationDyslipidemia Treatment in 2016 Novel Agents Combination Therapies Statin Intolerance
Dyslipidemia Treatment in 2016 Novel Agents Combination Therapies Statin Intolerance Hani Sabbour MD FACC FHRS Clinical Assistant Professor of Cardiology Brown University Rhode Island USA Consultant Cardiology
More informationNew Drugs and Technologies
New Drugs and Technologies Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk Nathalie Bergeron, PhD; Binh An P. Phan, MD; Yunchen
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More information